Trial NCT05320380

View at ClinicalTrials.gov 
Org. Study IDs: APAL2020B
Secondary IDs: APAL2020B NCI-2022-02157 U10CA180886

Last trial update was posted on 2023-09-01

MeSH Interventions

Cortisone Cytarabine Daunorubicin Fludarabine Fludarabine phosphate Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Methotrexate Methylprednisolone Methylprednisolone Acetate Methylprednisolone Hemisuccinate Prednisolone Prednisolone acetate Prednisolone hemisuccinate Prednisolone phosphate

MeSH Conditions

Acute Disease Leukemia Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myeloid, Acute Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Recurrence

Other Conditions

Recurrent Acute Myeloid Leukemia Recurrent B Acute Lymphoblastic Leukemia Recurrent Mixed Phenotype Acute Leukemia Recurrent T Acute Lymphoblastic Leukemia Refractory Acute Myeloid Leukemia Refractory B Acute Lymphoblastic Leukemia Refractory Mixed Phenotype Acute Leukemia Refractory T Acute Lymphoblastic Leukemia

Stopping Reasons

Withdrawn per CS0150757

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID